Charles River Laboratories International, Inc. (CRL)
| Market Cap | 8.79B |
| Revenue (ttm) | 4.02B |
| Net Income (ttm) | -144.34M |
| Shares Out | 49.23M |
| EPS (ttm) | -2.91 |
| PE Ratio | n/a |
| Forward PE | 16.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,198,181 |
| Open | 172.08 |
| Previous Close | 175.46 |
| Day's Range | 170.00 - 179.82 |
| 52-Week Range | 91.86 - 228.88 |
| Beta | 1.62 |
| Analysts | Buy |
| Price Target | 197.58 (+10.7%) |
| Earnings Date | Feb 18, 2026 |
About CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, ins... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $197.58, which is an increase of 10.70% from the latest price.
News
Charles River raises annual profit view as it sells underperforming assets
Contract drug developer Charles River Laboratories raised its 2026 profit forecast on Wednesday, after it announced the sales of some underperforming assets to peer IQVIA and private equity firm GI Pa...
Charles River Laboratories Provides Update on Planned Divestitures
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Update on Planned Divestitures.
Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
Charles River Laboratories Q4 Review: Approaching A Bottom
Charles River Laboratories Q4 Review: Approaching A Bottom
Charles River forecasts upbeat 2026 profit on improved demand for drug development services
Contract drug developer Charles River Laboratories on Wednesday forecast annual profit above Wall Street estimates, betting on an improvement in demand for its drug discovery and development services ...
Charles River Laboratories Announces Executive Appointments
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Executive Appointments.
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance.
Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your right...
Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call.
Charles River Enters Manufacturing Collaboration with Gazi University
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Gazi University Faculty of Medicine, today announced a gene therapy contract developme...
Charles River Laboratories Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL
NEW YORK and NEW ORLEANS, Jan. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Charles River to buy Cambodia-based monkey supplier for $510 million
Charles River Laboratories said on Monday it would buy one of its major suppliers of non-human primates for about $510 million as the contract research firm seeks greater control over procurement of t...
Charles River Laboratories Provides Business Updates
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Business Updates.
Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan.
Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Laun...
T. Rowe Price Transitions to Charles River's Enterprise Multi-Asset Investment Management Platform
BOSTON--(BUSINESS WIRE)--Charles River Development, a State Street Company, announced today the expansion of its relationship with T. Rowe Price through the migration to the SaaS-deployed Charles Rive...
Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript
HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...
Charles River Laboratories to Present at Evercore Healthcare Conference
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Evercore Healthcare Conference.
Madison Small Cap Fund Q3 2025 Portfolio Activity
The small cap team initiated a new investment position in Hexcel Corporation. Hexcel is a global leader in advanced composite materials. We initiated a position in Charles River Labs in Q3. CRL is a h...
Charles River Laboratories International, Inc. (CRL) Presents at Jefferies London Healthcare Conference 2025 Transcript
Charles River Laboratories International, Inc. ( CRL) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Birgit Girshick - Corporate Executive VP & COO Con...
SOLVE and Charles River Development Partner to Deliver Integrated Fixed Income Pricing for Investment Managers
STAMFORD, Conn.--(BUSINESS WIRE)--SOLVE, the leading provider of pre-trade data and predictive pricing for fixed income securities markets, today announced a new partnership with Charles River Develop...
Charles River Laboratories to Present at Jefferies Global Healthcare Conference
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Jefferies Global Healthcare Conference.
Charles River Laboratories International, Inc. (CRL) Q3 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. ( CRL) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foste...